RA Capital Management’s Acrivon Therapeutics ACRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.93M | Hold |
8,340,508
| – | – | 0.17% | 46 |
|
|
2025
Q1 | $16.9M | Hold |
8,340,508
| – | – | 0.28% | 48 |
|
|
2024
Q4 | $50.2M | Hold |
8,340,508
| – | – | 0.67% | 31 |
|
|
2024
Q3 | $58.4M | Hold |
8,340,508
| – | – | 0.67% | 33 |
|
|
2024
Q2 | $48.4M | Buy |
8,340,508
+3,530,000
| +73% | +$20.5M | 0.64% | 39 |
|
|
2024
Q1 | $34.4M | Hold |
4,810,508
| – | – | 0.44% | 49 |
|
|
2023
Q4 | $23.7M | Hold |
4,810,508
| – | – | 0.37% | 44 |
|
|
2023
Q3 | $46M | Hold |
4,810,508
| – | – | 0.91% | 33 |
|
|
2023
Q2 | $62.3M | Hold |
4,810,508
| – | – | 1.18% | 26 |
|
|
2023
Q1 | $61M | Hold |
4,810,508
| – | – | 1.38% | 25 |
|
|
2022
Q4 | $55.4M | Buy |
+4,810,508
| New | +$55.4M | 1.12% | 26 |
|